Vimarsana
Biggest News Aggregation in the World

Page 8 - Thomas Equels News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Thomas Equels. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Thomas Equels Today - Breaking & Trending Today

AIM ImmunoTech CEO to Participate in Two Upcoming Investor - Vimarsana News

AIM ImmunoTech CEO to Participate in Two Upcoming Investor

OCALA, Fla., Dec. 06, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that Thomas Equels, Chief Executive Officer of...

BioFlorida Announces Five New Board Members - Vimarsana News

BioFlorida Announces Five New Board Members

/PRNewswire/ -- BioFlorida has announced five new board members who will support the organization's effort to grow the life sciences industry in Florida. "The...

AIM ImmunoTech Inc enters into two-year agreement extension with Shenzhen Smoore Technology Limited to develop Ampligen as a potential inhalation therapy for COVID-19 and other respiratory viral diseases - Vimarsana News

AIM ImmunoTech Inc enters into two-year agreement extension with Shenzhen Smoore Technology Limited to develop Ampligen as a potential inhalation therapy for COVID-19 and other respiratory viral diseases

AIM hopes to commence inhalation safety testing before year-end AIM entered into the material transfer and research agreement to study the utilization of an innovative Smoore inhalation delivery device AIM ImmunoTech Inc (NYSEAMERICAN:AIM) (FRA:HXB2) has entered into a two-year agreement extension with Shenzhen Smoore Technology Limited (Smoore) with the goal of developing Ampligen as a potential inhalation therapy for coronavirus (COVID-19) and other respiratory viral diseases.  In April 2020, AIM entered into the material transfer and research agreement to study the utilizatio...

NA Proactive news snapshot: Mydecine Innovations Group Inc, Aion Therapeutic Inc, EVmo Inc, Alpine 4 Holdings Inc, Dalrada Corporation , Ayurcann Holdings Corp, HempFusion Wellness Inc, Fireweed Zinc Ltd, Fury Gold Mines Ltd, Ridgeline Minerals Corp, AIM - Vimarsana News

NA Proactive news snapshot: Mydecine Innovations Group Inc, Aion Therapeutic Inc, EVmo Inc, Alpine 4 Holdings Inc, Dalrada Corporation , Ayurcann Holdings Corp, HempFusion Wellness Inc, Fireweed Zinc Ltd, Fury Gold Mines Ltd, Ridgeline Minerals Corp, AIM

A glance at some of the day's highlights from the Proactive Investors US and Canada newswires Your daily round-up from the world of Proactive Mydecine Innovations Group Inc (NEO:MYCO) (OTCMKTS:MYCOF) (FRA:0NFA) announced that it ended the first quarter of 2021 with cash and equivalents of C$11.3 million, which the company said will help it advance its intellectual property portfolio, build out its clinical trial calendar, expand its European operations and develop its technology division. As well, Mydecine said its strategic partnerships are expected to expand its drug development...

AIM reports positive safety data from intranasal Covid-19 drug trial - Vimarsana News

AIM reports positive safety data from intranasal Covid-19 drug trial

8 April 2021 (Last Updated April 8th, 2021 08:00) AIM ImmunoTech has reported that no serious adverse events were observed in Cohort 1 of a Phase I AMP-COV-100 (CHDR2049) clinical study of its drug Ampligen as an intranasal therapy for Covid-19. With this latest development, the company will soon initiate dose escalation in Cohort 2 of the trial. Credit: Gerd Altmann from Pixabay. Share Article AIM ImmunoTech has reported that no serious adverse events were observed in Cohort 1 of a Phase I AMP-COV-100 (CHDR2049) clinical study of its drug Amplig...